Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000270166 | SCV000330958 | likely benign | not specified | 2015-09-25 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000588771 | SCV000695696 | likely benign | not provided | 2016-02-19 | criteria provided, single submitter | clinical testing | Variant summary: The GALT c.564+15G>A variant affects a non-conserved intronic nucleotide not widely known to impact normal splicing. Mutation Taster predicts a benign outcome for this variant, and 4/5 Alamut algorithms predict no change to the splice donor site, however these in silico predictions have not been verified with functional studies. This variant is found in 48/121384 control chromosomes at a frequency of 0.0003954, which does not significantly exceed maximal expected frequency of a pathogenic allele (0.0028868). This variant has been cited in one Hispanic classic GALT patient (Yang_HM_2002), authors did not provide co-segregation data, and the allele frequency in Latinos from the ExAC project is 2-fold greater (48/11576 alleles; 0.00415), thus this variant is likely a benign polymorphism found in Latinos. Additionally, multiple clinical labs/databases classify the variant as benign/likely benign without providing evidence to independently evaluate. Taken together, the variant was classified as Likely Benign until additional information becomes available. |
Labcorp Genetics |
RCV002054469 | SCV002468285 | benign | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2025-01-30 | criteria provided, single submitter | clinical testing |